Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs First Solar, Inc. (FSLR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs First Solar, Inc. — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $227.17 (market cap $29.97B), while First Solar, Inc. trades at $224.5 (market cap $25.89B). The key difference: Alnylam Pharmaceuticals, Inc. is the larger of the two by market cap, and First Solar, Inc. is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | FSLR | |
|---|---|---|
Market Cap | $29.97B | $25.89B |
Sector | Health | Technology |
52-Week High | $491.22 | $318.30 |
52-Week Low | $205.48 | $180.05 |
Enterprise Value | $27.93B | $24.36B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $227.12, up 2.68% in the last 24 hours, but technical indicators signal a bearish trend with resistance near $229. The company reported strong revenue growth to $3.71B in 2025 and turned profitable with a net income of $313.75M, though recent Q2 2026 earnings missed estimates. Multiple law firms are investigating potential securities fraud, adding to negative sentiment.
Outlook is mixed: analyst consensus remains bullish with a $370.07 price target, but risks include ongoing legal probes, earnings volatility, and high valuation multiples. The stock faces near-term pressure from bearish technicals and investor caution despite solid fundamental progress.
First Solar (FSLR) trades at $223.69, down 7.15% amid a class action lawsuit alleging securities fraud from February 2025 to February 2026. Technically, the stock is bearish with support at $215 and resistance at $228. Fundamentally, revenue grew to $5.22B in 2025 with a net income margin of 29.27%, though Q4 2025 EPS missed expectations. Analyst consensus is bullish with a $282.07 price target, but legal risks cloud near-term sentiment.
The outlook is mixed: strong profitability and growth support upside, but the lawsuit and bearish technicals pose risks. Investors should weigh robust fundamentals against legal uncertainties and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About First Solar, Inc.
First Solar designs and manufactures solar photovoltaic panels, modules, and systems for use in utility-scale development projects. The company's solar modules use cadmium telluride to convert sunlight into electricity. This is commonly called thin-film technology. First Solar is the world's largest thin-film solar module manufacturer. It has production lines in Vietnam, Malaysia, the United States, and a new factory under construction in India.
Read more on FSLR →
